Administration of urea compounds for combating signs of cutaneous aging
Signs of aging of the skin and/or mucous membranes are prevented and/or reduced, and the activity of the proteolytic enzymes of the stratum corneum are stimulated as well, by administering to an individual in need of such treatment, a cosmetic/pharmaceutical composition which comprises a thus effective amount of at least one hydroxylated urea compound having the following formula (I): in which: the radicals R1, R2, R3 and R4, which may be identical or different, are each a hydrogen atom, a C 1 -C 4 alkyl radical or a C 2 -C 6 hydroxyalkyl radical which can contain from 1 to 5 hydroxyl groups, wherein at least one of the R1 to R4 radicals represents a hydroxyalkyl radical, or salt, solvate or isomer thereof, formulated into a physiologically acceptable medium therefor.
1. A regime or regimen for regulating epidermal differentiation, and/or inhibiting the reduction in the amount of free amino acids in the stratum corneum related to age, and/or reducing the age-related accumulation of abnormal proteins, the regime or regimen comprising:
administering to an individual in need of such treatment, a cosmetic/pharmaceutical composition which comprises a thus effective amount of at least one hydroxylated urea compound having the following formula (I):
in which:
the radicals R1, R2, R3 and R4, which may be identical or different, are each a hydrogen atom, a C 1 -C 4 alkyl radical or a C 2 -C 6 hydroxyalkyl radical which can contain from 1 to 5 hydroxyl groups, wherein at least one of the R1 to R4 radicals represents a hydroxyalkyl radical, or salt, solvate or isomer thereof, formulated into a physiologically acceptable medium therefor; and
regulating epidermal differentiation, and/or inhibiting the reduction in the amount of free amino acids in the stratum corneum related to age, and/or reducing the age-related accumulation of abnormal proteins; and
said effective amount of the compound of formula (I) is an amount equivalent to that observed in an in vitro measurement of protease activity for the same compound at concentrations of from 1M to 4M.
2. The regime or regimen as defined by claim 1 , for regulating epidermal differentiation.
3. The regime or regimen as defined by claim 1 , for inhibiting the reduction in the amount of free amino acids in the stratum corneum related to age.
4. The regime or regimen as defined by claim 1 , for reducing the age-related accumulation of abnormal proteins.
5. The regime or regimen as defined by claim 1 , said cosmetic/pharmaceutical composition further comprising at least one active agent which reduces and/or inhibits the activity of harmful proteases.
6. The regime or regimen as defined by claim 5 , said cosmetic/pharmaceutical composition further comprising at least one active agent which inhibits MMPs and/or at least one active agent which inhibits the activation of plasminogen.
7. The regime or regimen as defined by claim 1 , wherein formula (I), R1 is a C 2 -C 6 hydroxyalkyl radical and R2, R3 and R4, which may be identical or different, are each a hydrogen atom or a C 1 -C 4 alkyl radical.
8. The regime or regimen as defined by claim 1 , wherein formula (I), R1 is a C 2 -C 6 hydroxyalkyl radical having from 1 to 5 hydroxyl groups and R2, R3 and R4 are each a hydrogen atom.
9. The regime or regimen as defined by claim 1 , wherein formula (I), R1 is a C 2 -C 6 hydroxyalkyl radical having 1 hydroxyl group.
10. The regime or regimen as defined by claim 1 , wherein formula (1), R1 is a C 2 -C 4 hydroxyalkyl radical having 1 hydroxyl group and R2, R3 and R4 are each a hydrogen atom.
11. The regime or regimen as defined by claim 1 , said at least one hydroxylated urea compound of formula (1) being selected from the group consisting of N-(2-hydroxyethyl)urea; N-(2-hydroxypropyl)urea; N-(3-hydroxypropyl)urea; N-(2,3-dihydroxypropyl)urea; N-(2,3,4,5,6-penta-hydroxyhexyl)urea; N-methyl-N-(1,3,4,5,6-pentahydroxy-2-hexyl)urea; N-methyl-N′-(1-hydroxy-2-methyl-2-propyl)urea; N-(1-hydroxy-2-methyl-2-propyl)urea; N-(1,3-dihydroxy-2-propyl)urea; N4-tris(hydroxy-methyl)methyl]urea; N-ethyl-N′-(2-hydroxyethyl)urea; N,N-bis(2-hydroxyethyl)urea; N,N′-bis(2-hydroxyethyl)urea, N,N-bis(2-hydroxypropyl)urea; N,N′-bis(2-hydroxypropyl)urea; N,N-bis(2-hydroxyethyl)-N′-propylurea; N,N-bis(2-hydroxypropyl)-N′-(2-hydroxyethyl)urea; N-(tert-butyl)-N′-(2-hydroxyethyl)-N′-(2-hydroxypropyl)urea; N-(1,3-dihydroxy-2-propy1)-N′-(2-hydroxyethyl)urea; N,N-bis(2-hydroxyethyl)-N′,N′-dimethylurea; N,N,N′,N′-tetrakis(2-hydroxyethyl)urea; N′,N′-bis(2-hydroxyethyl)-N′,N′-bis(2-hydroxypropyl)urea; and mixtures thereof.
12. The regime or regimen as defined by claim 11 , said at least one hydroxylated urea compound of formula (1) being N-(2-hydroxyethyl)urea.
13. The regime or regimen as defined by claim 1 , comprising topically applying said cosmetic/pharmaceutical composition onto the skin and/or mucous membranes of said individual.
14. The regime or regimen as defined by claim 1 , said cosmetic/pharmaceutical composition being formulated for administration by injection.
15. The regime or regimen as defined by claim 1 , said cosmetic/pharmaceutical composition being formulated for administration by oral ingestion.
16. The regime or regimen as defined by claim 1 , further comprising: reducing pigmentations and actinic keratoses.
17. The regime or regimen as defined by claim 1 , further comprising: treating loss of firmness and/or elasticity of the skin.